



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53686

Title: Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Reviewer's code: 03699961

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's country: Japan

Author's country: Argentina

Manuscript submission date: 2019-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2019-12-29 11:04

Reviewer performed review: 2019-12-30 14:28

Review time: 1 Day and 3 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Title: Sequencing of systemic treatment for hepatocellular carcinoma: second line competitors. Federico Piñero, Marcelo Silva and Massimo Iavarone. 1) General Comments In this manuscript, the authors reviewed molecular targeting therapies against hepatocellular carcinoma especially second line therapies in mind. Ample information is concisely summarized to meet clinical setting. It would be beyond the focus, however, of this manuscript to discuss if regulatory agencies should approve tyrosine kinase inhibitors and/or immunotherapy agents for the treatment of hepatocellular carcinoma. The followings are concerns that the authors may wish to consider: 2) Specific comments Major concerns: 1. Scientific evidence is not exclusive determinant for the approval of medicine by regulatory agencies especially for expensive drugs such as tyrosine kinase inhibitors and/or immunotherapy agents. The decision should be made to achieve the best performance of health and welfare in each society under the limited budget. In terms of a medication, which leads to survival benefit but not cure, it is arrogant to criticize the unapproved regulation in several countries. Minor concerns: 1. In the Table 1, there is no data for lenvatinib. 2. In the 8th paragraph of "FIRST LINE SYSTEMIC TREATMENT" section, the sentence, "However, these endpoints were not contemplated, even as a secondary objectives" is unclear. Please rewrite it.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

[Y] No

BPG Search:

[] The same title

[] Duplicate publication

[] Plagiarism

[Y] No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53686

Title: Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Reviewer's code: 02832130

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor

Reviewer's country: China

Author's country: Argentina

Manuscript submission date: 2019-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2019-12-29 01:29

Reviewer performed review: 2020-01-01 15:19

Review time: 3 Days and 13 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The author reviewed the systemic treatment options in first and second line for advanced HCC in this manuscript. The subject of this manuscript is of value, but there are defects (text typesetting) need to be modified, some have been marked. See attached.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53686

Title: Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Reviewer's code: 03647881

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Attending Doctor

Reviewer's country: Taiwan

Author's country: Argentina

Manuscript submission date: 2019-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2019-12-30 00:08

Reviewer performed review: 2020-01-05 14:39

Review time: 6 Days and 14 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Excellent review, thanks.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53686

Title: Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Reviewer’s code: 03647931

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor, Doctor

Reviewer’s country: Egypt

Author’s country: Argentina

Manuscript submission date: 2019-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2019-12-29 10:45

Reviewer performed review: 2020-01-08 10:29

Review time: 9 Days and 23 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This review article by Piñero F et al, " Sequencing of systemic treatment for hepatocellular carcinoma: second line competitors. The paper is quite interesting, very well written and informative. The knowledge is up to date, the figures and tables and clear. However, I have only one comment. I suggest that the authors add one more figure, an algorithm or flow chart showing the plan of using systemic therapy including treatment duration, does reduction rules and when to start second line agents.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No